TrialOncotarget2015

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Eveline M Dijkgraaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.